Trials / Completed
CompletedNCT03009292
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study E7080-C086-108 is an open-label, single- and multiple-dose pharmacokinetic (PK) study of lenvatinib (administered orally, once a day \[QD\]) in Chinese participants with solid tumor. A total of 12 participants will be enrolled to evaluate the PK of 24 milligrams (mg) QD dosing of lenvatinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lenvatinib | once daily continuous dosing |
Timeline
- Start date
- 2018-08-06
- Primary completion
- 2018-12-24
- Completion
- 2021-08-27
- First posted
- 2017-01-04
- Last updated
- 2021-09-28
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03009292. Inclusion in this directory is not an endorsement.